Description About Product Tamoximed Balkan Pharmaceuticals
- Manufacturer: Balkan Pharmaceuticals
- Other Brand Names: Nolvadex
- Chemical Formula: 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
- Concentration: 20 mg
- Package: 60 pills
- Shipping time:
- EU (Italy, UK, Germany, Spain, France) 5-15 days,
- UK 5-15 days,
- US 15-21 days,
- Canada 15-21 days.
Tamoximed Balkan Pharmaceuticals is a drug for recovering hormonal balance after steroid use. Almost any steroid cycle leads to a rise in estrogen and a drop in testosterone. Sure, that has a negative influence on an athlete’s health. So, he should restore his hormonal balance within the shortest term. Otherwise, that may lead to swelling, blood hypertension, fat gains, breast enlargement, muscle loss, fatigue, erectile problems. The main ingredient of this product ― Tamoxifen ― belongs to SERMs. This substance works by blocking estrogen receptors. So, this sex hormone cannot attach to them. Thus, its level decreases. Besides, it stimulates testosterone synthesis. As a result, the symptoms mentioned above go away.
Medical Uses
This medication produces a complex impact on breast oncology. It both prevents tumors from appearing and stops their development.
Sport Uses
A course of this PCT supplement should start 3-4 weeks after a steroid cycle is over. Also, most specialists recommend combining Tamoximed Balkan Pharmaceuticals with another antiestrogen. The point is that it does not block aromatization. So, when one stops using it, estrogen levels will increase. Sure, the corresponding side effects will return as well. Thus, to avoid that, one should add Provimed to post-course therapy.
Side Effects:
One must mention menstrual disorders, prostate problems, male alopecia, mood swings, blood hypertension.
Pharmacology
Tamoximed Balkan Pharmaceuticals is a drug with high antiestrogenic activity.
Warnings
If you do not want to face severe health problems, be sure to get recommendations on its use from a medical professional.
Reviews
There are no reviews yet.